A clinical trial evaluating the efficacy and safety of Lutetium-treatment for advanced neuroendocrine tumors

• Conditions: Metastatic neuroendocrine tumors; MedDRA version: 17.1Level: PTClassification code 10052399Term: Neuroendocrine tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps); Therapeutic area: Diseases [C] - Cancer [C04]

• Registration Number: EUCTR2011-000240-16-SE
• Lead Sponsor: Skånes Onkologiska Klinik, Skåne University Hospital, Lund

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2011-04-07
• Last Update Posted: 23 March 2015

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Are the trial subjects under 18? no
Number of subjects for this age range: 0
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 70
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 30

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: ;Secondary Objective: ;Primary end point(s):